From professional translators, enterprises, web pages and freely available translation repositories.
leveraminotransferaser
liver aminotransferases
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
forhøjede leveraminotransferaser
hepatic transaminase elevations
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
forhøjelse af leveraminotransferaser
hepatic transaminase elevations
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
forhøjede leveraminotransferaser i blodet
increased liver transaminases in your blood
Last Update: 2017-04-26
Usage Frequency: 2
Quality:
unormal leverfunktion, forhøjede leveraminotransferaser.
hepatic function abnormal, transaminases increased.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
der blev observeret forhøjede leveraminotransferaser i placebokontrollerede studier.
in placebo-controlled studies, elevations of hepatic transaminases were observed.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
forhøjede leveraminotransferaser, vægtøgning, øget total- bilirubin*
hepatic transaminases increased, weight increased, total bilirubin increased
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
forbigående, asymptomatisk forhøjede leveraminotransferaser (alat, asat), særlig
transient, asymptomatic elevations of hepatic aminotransferases
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
· basislinieværdier for leveraminotransferaser, dvs. aspartataminotransferaser (asat) og/eller
· baseline values of liver aminotransferases, i. e., aspartate aminotransferases (ast) and/or
Last Update: 2008-03-04
Usage Frequency: 2
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
klinisk status, herunder niveauet af leveraminotransferaser og bilirubin, bør overvåges.
clinical status including liver aminotransferases and bilirubin should be monitored.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
den kliniske status, herunder niveauet af leveraminotransferaser og bilirubin, bør overvåges.
clinical status including liver aminotransferases and bilirubin should be monitored.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
patienter med baselineværdier for leveraminotransferaser (asat og/eller alat) 3 x uln.
patients with baseline values of hepatic aminotransferases (ast and/or alt) 3x uln.
Last Update: 2008-03-04
Usage Frequency: 1
Quality:
Warning: This alignment may be wrong.
Please delete it you feel so.
forbigående, asymptomatiske forhøjelser af leveraminotransferaser alat og asat er almindeligt forekommende, især initialt i behandlingen.
transient, asymptomatic elevations of hepatic aminotransferases, alt, ast have been seen commonly, especially in early treatment.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
bosentan har været forbundet med dosisrelaterede forøgelser af leveraminotransferaser, dvs. aspartat - og alaninaminotransferaser.
bosentan has been associated with dose-related elevations in liver aminotransferases, i.e., aspartate and alanine aminotransferases.
Last Update: 2012-04-12
Usage Frequency: 4
Quality:
tracleer må ikke bruges samtidigt med glibenclamid på grund af en øget risiko for forhøjede leveraminotransferaser (se pkt.
tracleer should not be used concomitantly with glibenclamide, due to an increased risk of elevated liver aminotransferases (see section 4.5).
Last Update: 2012-04-12
Usage Frequency: 4
Quality:
i tilfælde af en signifikant forhøjelse af leveraminotransferaser bør dosis af esbriet justeres, eller behandlingen afbrydes efter nedenstående retningslinjer.
in the event of significant elevation of liver aminotransferases the dose of esbriet should be adjusted or treatment discontinued according to the guidelines listed below.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
den øgede hyppighed af forhøjede leveraminotransferaser hos patienter behandlet med tecfidera i forhold til placebo sås primært i de første 6 måneder af behandlingen.
the increased incidence of elevations of hepatic transaminases in patients treated with tecfidera relative to placebo was primarily seen during the first 6 months of treatment.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
i det kliniske program forekom dosisafhængige stigninger i leveraminotransferaser generelt inden for de første 26 uger af behandlingen, i reglen udviklet gradvist og hovedsageligt asymptomatisk.
in the clinical programme, dose-dependent elevations in liver aminotransferases generally occurred within the first 26 weeks of treatment, usually developed gradually, and were mainly asymptomatic.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
under administration af simeprevir sammen med peginterferon alfa og ribavirin var stigningerne i direkte og indirekte bilirubin generelt ikke forbundet med stigninger i leveraminotransferaser og blev normaliseret efter afslutning af behandlingen.
during administration of simeprevir with peginterferon alfa and ribavirin, the elevations in direct and indirect bilirubin were generally not associated with elevations in liver transaminases and normalised after end of treatment.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
stigninger i leveraminotransferaser (asat, alat) er blevet forbundet med pah og med endothelinreceptorantagonister (era’er).
elevations of liver aminotransferases (ast, alt) have been associated with pah and with endothelin receptor antagonists (eras).
Last Update: 2017-04-26
Usage Frequency: 1
Quality: